A Blueprint for High Affinity SARS-CoV-2 Mpro Inhibitors from Activity-Based Compound Library Screening Guided by Analysis of Protein Dynamics

Autor: Gossen J., Albani S., Hanke A., Joseph B. P., Bergh C., Kuzikov M., Costanzi E., Manelfi C., Storici P., Gribbon P., Beccari A. R., Talarico C., Spyrakis F., Lindahl E., Zaliani A., Carloni P., Wade R. C., Musiani F., Kokh D. B., Rossetti G.

Publikováno v: ACS Pharmacology & Translational Science
ACS pharmacology & translational science 4(3), 1079–1095 (2021). doi:10.1021/acsptsci.0c00215

The SARS-CoV-2 coronavirus outbreak continues to spread at a rapid rate worldwide. The main protease (Mpro) is an attractive target for anti-COVID-19 agents. Unexpected difficulties have been encountered in the design of specific inhibitors. Here, by

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::5b75cc9e2e8c06cd8c4e708948150195
http://europepmc.org/articles/PMC8009102